Glenmark: Strong growth continues - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark: Strong growth continues

Feb 11, 2002

Glenmark Pharma continues to outperform industry growth rates. The company has recorded a 31% growth in topline. Profit before tax registered a growth of 54%, on the back of sharp rise in operating margins. Depreciation and Interest showed a sharp spurt however, on account of commissioning of its new Goa facility. The company has also performed impressively on the export front.

(Rs m)3QFY013QFY02% Change9m FY019m FY02% Change
Sales50966730.9% 1,430 1,710 19.6%
Other Income51-87.5% 9 2 -79.6%
Expenditure41752525.9% 1,206 1,353 12.2%
Operating Profit (EBDIT) 92 142 53.5% 224 357 59.1%
Operating Profit Margin (%)18.1%21.3% 15.7%20.9%
Interest 293314.0% 56 95 69.0%
Depreciation112290.1% 28 64 128.1%
Profit before Tax 57 88 54.4% 149 200 34.2%
Tax533574.0% 13 40 217.5%
Profit after Tax/(Loss) 52 55 5.3% 136 160 17.4%
Net profit margin (%)10.2%8.2% 9.5%9.4% 
No. of Shares (eoy) (m)10.110.1 10.110.1 
Diluted Earnings per share*20.721.8 18.021.1 
P/E (at current price) 11.8  12.1 
(*- annualised)      

To strengthen its position in the dermatology and respiratory segments, the company had acquired three large brands of Lyka Laboratories last year for a consideration of Rs 345 m. These include Alex (cough preparation), Flucort (dermatology steroid) and Sensur (pain balm). All the three brands have performed well during the year. The company is consicously reducing its dependence on the dermatology segment by launching products across various therapeutic segment. Some of the company's products launched in the anti-diabetes and cardiovascular segment seem to be doing well.

R&D efforts of the company also seem to be progressing well. The research activities of the company are focused in the areas of diabetes, asthma and pain management.Two molecules of the company are in advanced pre-clinical trial stage.

  • Read our recent company update

    It seems that the company is taking all the right steps to maintain its growth trajectory in future. However, while growth in the domestic market is hard to come, the company is a bit late in cashing on the generic opportunity as it lacks an ANDA (Abbreviated New Drug Application) pipeline. In the domestic market on the other hand, the company faces stiff competition and it would be hard to maintain premium pricing going forward. Considering other peer valuations and a P/E multiple of 12x 9 months annualised earnings, the stock looks fairly valued at the current market price of Rs 255.

  • Equitymaster requests your view! Post a comment on "Glenmark: Strong growth continues". Click here!

      

    More Views on News

    GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

    Sep 6, 2021 | Updated on Sep 6, 2021

    Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

    GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

    Aug 16, 2021 | Updated on Aug 16, 2021

    For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

    5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

    Dec 3, 2021

    As the new variant of Covid-19 emerges, keep an eye on these stocks.

    This Stock Just Made a Historical Debut on the Exchanges (Views On News)

    Nov 15, 2021

    Shares of the company listed at premium of 253% from its IPO price, the highest ever.

    3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

    Nov 9, 2021

    In 2021, R&D of pharma companies roared to life in a never-before-seen way.

    More Views on News

    Most Popular

    Infosys vs TCS: Which is Better? (Views On News)

    Nov 26, 2021

    In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

    This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

    Nov 24, 2021

    Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

    6 Popular Stocks that Turned into Penny Stocks (Views On News)

    Nov 27, 2021

    A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

    MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

    Nov 20, 2021

    The Rs 19 bn issue is set to hit the market soon.

    5 Indian Companies Embracing Blockchain Technology (Views On News)

    Nov 23, 2021

    Blockchain adoption in India was slow in the past. Now, the technology is being well received.

    More

    Become A Smarter Investor
    In Just 5 Minutes

    Multibagger Stock Guide 2022
    Get our special report Multibagger Stocks Guide (2022 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GLENMARK PHARMA SHARE PRICE


    Dec 3, 2021 (Close)

    TRACK GLENMARK PHARMA

    • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON GLENMARK PHARMA

    GLENMARK PHARMA - VENUS REMEDIES COMPARISON

    COMPARE GLENMARK PHARMA WITH

    MARKET STATS